. 2006 Jun 29;97(9):813–820. doi: 10.1111/j.1349-7006.2006.00265.x

Table 2.

Relationship between various parameters and clinical response to docetaxel in human breast cancers

Parameter	Category	No. patients ^†	Response rate (%) ^‡	P‐value
ER	Positive	32	56	0.862
ER	Negative	37	57
HER2	Positive	13	69	0.193
HER2	Negative	49	49
P‐glycoprotein	Positive	26	54	0.987
P‐glycoprotein	Negative	37	54
MIB‐1	Positive	39	49	0.354
MIB‐1	Negative	23	60
BRCA1	Positive	47	53	0.794
BRCA1	Negative	14	57
BCL2	Positive	17	70	0.144
BCL2	Negative	46	50
p53	Positive	29	55	0.961
p53	Negative	33	54
β‐Tubulin III	Positive	14	28	<0.05
β‐Tubulin III	Negative	42	59
CYP3A4	Positive	16	19	<0.01
CYP3A4	Negative	15	67
Thioredoxin	Positive	14	21	0.018
Thioredoxin	Negative	49	63

^{^†}

Patients with large primary breast cancers or locally recurrent breast cancers.

^{^‡}

^‡ Patients who showed a complete or partial clinical response were considered to be responders.